EP1144997A3 - Methodes et composes de modulation d'activite de recepteurs nucleaires - Google Patents

Methodes et composes de modulation d'activite de recepteurs nucleaires

Info

Publication number
EP1144997A3
EP1144997A3 EP99916206A EP99916206A EP1144997A3 EP 1144997 A3 EP1144997 A3 EP 1144997A3 EP 99916206 A EP99916206 A EP 99916206A EP 99916206 A EP99916206 A EP 99916206A EP 1144997 A3 EP1144997 A3 EP 1144997A3
Authority
EP
European Patent Office
Prior art keywords
compounds
methods
receptor activity
nuclear receptor
modulating nuclear
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP99916206A
Other languages
German (de)
English (en)
Other versions
EP1144997A2 (fr
Inventor
Andrew Shiau
Peter J. Kushner
David A. Agard
Geoffrey L. Greene
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California
Arch Development Corp
Original Assignee
University of California
Arch Development Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of California, Arch Development Corp filed Critical University of California
Publication of EP1144997A2 publication Critical patent/EP1144997A2/fr
Publication of EP1144997A3 publication Critical patent/EP1144997A3/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6875—Nucleoproteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • C07K14/721—Steroid/thyroid hormone superfamily, e.g. GR, EcR, androgen receptor, oestrogen receptor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • G01N33/78—Thyroid gland hormones, e.g. T3, T4, TBH, TBG or their receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/72—Assays involving receptors, cell surface antigens or cell surface determinants for hormones
    • G01N2333/723—Steroid/thyroid hormone superfamily, e.g. GR, EcR, androgen receptor, oestrogen receptor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/20—Screening for compounds of potential therapeutic value cell-free systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Obesity (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Reproductive Health (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Cardiology (AREA)
EP99916206A 1998-03-30 1999-03-30 Methodes et composes de modulation d'activite de recepteurs nucleaires Withdrawn EP1144997A3 (fr)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US7995698P 1998-03-30 1998-03-30
US79956P 1998-03-30
US11301498P 1998-12-16 1998-12-16
US11314698P 1998-12-16 1998-12-16
US113146P 1998-12-16
US113014P 1998-12-16
PCT/US1999/006937 WO1999050658A2 (fr) 1998-03-30 1999-03-30 Methodes et composes de modulation d'activite de recepteurs nucleaires

Publications (2)

Publication Number Publication Date
EP1144997A2 EP1144997A2 (fr) 2001-10-17
EP1144997A3 true EP1144997A3 (fr) 2002-08-28

Family

ID=27373576

Family Applications (1)

Application Number Title Priority Date Filing Date
EP99916206A Withdrawn EP1144997A3 (fr) 1998-03-30 1999-03-30 Methodes et composes de modulation d'activite de recepteurs nucleaires

Country Status (6)

Country Link
EP (1) EP1144997A3 (fr)
JP (1) JP2002516983A (fr)
KR (1) KR20010042373A (fr)
AU (1) AU3457199A (fr)
CA (1) CA2324060A1 (fr)
WO (1) WO1999050658A2 (fr)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1068529A4 (fr) * 1998-03-30 2004-08-04 Univ California Methodes et composes de modulation de la liaison d'un coactivateur a des recepteurs nucleaires
WO2000052050A2 (fr) * 1999-03-01 2000-09-08 Karo Bio Ab Modeles d'homologie du recepteur de glucocorticoide
AU775928B2 (en) * 1999-10-14 2004-08-19 Bristol-Myers Squibb Company Crystallographic structure of the androgen receptor ligand binding domain
FR2801311B1 (fr) * 1999-11-22 2005-08-26 Centre Nat Rech Scient Polypeptides derives du recepteur nucleaire de la vitamine d, et leurs utilisations notamment dans le cadre du criblage d'analogues de la vitamine d
EP1297175A4 (fr) * 2000-06-30 2005-02-02 Univ California Procedes et composes pour moduler la fixation de coactivateurs a des recepteurs nucleaires
DE10036461A1 (de) * 2000-07-25 2002-02-07 Bayer Ag Ligandenbindedomäne des Ultraspiracle (USP)-Proteins
JP4593754B2 (ja) * 2000-10-13 2010-12-08 一般財団法人 化学物質評価研究機構 化学物質の５０％阻害濃度決定方法
JP2002296282A (ja) * 2001-04-02 2002-10-09 Enbiotec Laboratories:Kk 外因性内分泌攪乱物質の検出方法
WO2003005025A1 (fr) * 2001-07-03 2003-01-16 Biovitrum Ab Procedes d'identification de composes modulant l'activite du ppar-gamma
GB0209507D0 (en) * 2002-04-25 2002-06-05 Karobio Ab Nuclear receptor structure
US7302347B2 (en) * 2002-12-10 2007-11-27 The Regents Of The University Of California Method for creating specific, high affinity nuclear receptor pharmaceuticals
WO2005022436A1 (fr) * 2003-08-29 2005-03-10 National Institute Of Advanced Industrial Science And Technology Systeme d'affichage tridimensionnel d'une structure proteique pour l'indication du mecanisme de manifestation de la fonction proteique
US7264813B2 (en) 2003-09-24 2007-09-04 Nikken Sohonsha Corporation Therapeutic uses of Dunaliella powder
CA2543329A1 (fr) * 2003-10-24 2005-05-06 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa Commutateurs geniques orthogonaux
CN105362151A (zh) 2010-03-31 2016-03-02 株式会社爱茉莉太平洋 含有香豆雌酚或包含香豆雌酚的豆提取物的、用于皮肤护理的化妆品组合物
BR112012031464A2 (pt) 2010-06-10 2020-08-04 Aragon Pharmaceuticals, Inc. moduladores do receptor de estrogênio e os seus usos
JP2015500346A (ja) 2011-12-14 2015-01-05 セラゴン ファーマシューティカルズ，インク． エストロゲン受容体モジュレーターおよびその使用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5650489A (en) * 1990-07-02 1997-07-22 The Arizona Board Of Regents Random bio-oligomer library, a method of synthesis thereof, and a method of use thereof
DK0604552T3 (da) * 1991-09-18 1997-08-04 Affymax Tech Nv Fremgangsmåde til syntese af forskellige samlinger af oligomerer
AU686186B2 (en) * 1993-05-27 1998-02-05 Aventisub Ii Inc. Topologically segregated, encoded solid phase libraries
IL106106A0 (en) * 1993-06-22 1993-10-20 Interpharm Lab Ltd Library of polymeric molecules and its preparation
CA2240024A1 (fr) * 1995-12-13 1997-06-19 The Regents Of The University Of California Ligands de recepteurs nucleaires et domaines de liaison de ligands

Also Published As

Publication number Publication date
KR20010042373A (ko) 2001-05-25
AU3457199A (en) 1999-10-18
EP1144997A2 (fr) 2001-10-17
JP2002516983A (ja) 2002-06-11
CA2324060A1 (fr) 1999-10-07
WO1999050658A3 (fr) 2001-08-16
WO1999050658A2 (fr) 1999-10-07

Similar Documents

Publication Publication Date Title
GB2327787B (en) Methods and systems for knowledge management
AU9790198A (en) Compounds and methods
AU6347498A (en) Catheter system for emboli containment
AU1556301A (en) Data distribution system and recorder for use therein
AU9298098A (en) Amino-substituted compounds, methods, and compositions for inhibiting parp activity
AU1651701A (en) Data distribution system and recorder for use therein
EP1144997A3 (fr) Methodes et composes de modulation d'activite de recepteurs nucleaires
IL136308A0 (en) Antipicornaviral compounds and methods for their use and preparation
AU9298198A (en) Di-n-heterocyclic compounds, methods, and compositions for inhibiting parp activity
AU7819598A (en) Soil testing assemblies
AU7134198A (en) Improved cell design for a trawl system and methods
AU2032397A (en) Biodecontamination reactor
AU5279798A (en) Urine bag assemblies
AU2668699A (en) Methods and compositions for modulating leptin activity
AU4109097A (en) Interaction area for data representation
AU1038599A (en) Method for secure storage management
HK1028665A1 (en) Apparatus for passbook management
AUPP696798A0 (en) Improved reactor
EP0882802A4 (fr) Procede d'evaluation de l'activite de la telomerase
AU1033397A (en) Biogas reactor
AU9167698A (en) Mini-stencil and device for using same
AU3852997A (en) Phenoxypropanolamines having beta3-adrenergic antagonist activity
AU6351298A (en) Containment system
AU9370998A (en) Transformer/reactor
AU8115298A (en) Catalytic reactor

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20001024

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

XX Miscellaneous

Free format text: DERZEIT SIND DIE WIPO-PUBLIKATIONSDATEN A3 NICHT VERFUEGBAR.

PUAK Availability of information related to the publication of the international search report

Free format text: ORIGINAL CODE: 0009015

AK Designated contracting states

Kind code of ref document: A3

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

17Q First examination report despatched

Effective date: 20050209

17Q First examination report despatched

Effective date: 20050209

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20061003